Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Blood (2020) 136 (Supplement 1): 37–38.

https://doi.org/10.1182/blood-2020-137575

Published: 2020

Journal Articles

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Louise Redder, MD, Tobias Wirenfeldt Klausen, M.S., Annette Juul Vangsted, MD PhD, Henrik Gregersen, MD PhD, Niels Frost Andersen, MD PhD, Robert Schou Pedersen, MD PhD, Torben Plesner, MD DSc, Mikael Frederiksen, MD, Ulf Christian Frølund, MD, Carsten Helleberg, MD, Lene Kongsgaard Nielsen, MD PhD, Morten Salomo, MD PhD, Peter Gimsing, MD DMSc, Henrik Frederiksen, MD PhD Prof, Niels Abildgaard, MD

Blood (2019) 134 (Supplement_1): 1849.

https://doi.org/10.1182/blood-2019-128074

Published: 2019

Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Blood (2017) 130 (Supplement 1): 3146.

https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146

Published: 2017

Journal Articles

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

Konstantinos Dimopoulos, MD, Peter Gimsing, MD PhD, Gangning Liang, Kirsten Grønbæk, Alexandra Helbo Søgaard, Ranjani Lakshminarasinham

Blood (2016) 128 (22): 3258.

https://doi.org/10.1182/blood.V128.22.3258.3258

Published: 2016

Journal Articles

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Blood (2016) 128 (14): 1821–1828.

https://doi.org/10.1182/blood-2016-07-726729

Published: 2016

Includes: Supplemental data

Journal Articles

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

Blood (2015) 126 (23): 727.

https://doi.org/10.1182/blood.V126.23.727.727

Published: 2015

Journal Articles

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Johan Lund, MD, Sigrid Karstorp, MD, Evren Alici, MD PhD, Astrid Gruber, MD PhD, Birgitta Lauri, MD, Cecilie Blimark, MD PhD, Agneta Swedin, MD PhD, Markus Hansson, MD PhD, Karin Forsberg, MD, Lucia Ahlberg, MD, Carlsson Conny, MD, Anders Waage, MD PhD, Peter Gimsing, Annette Juul Vangsted, MD PhD, Ulf Christian Frølund, MD, Mats Hardling, Ulf-Henrik Mellqvist, MD PhD, Hareth Nahi

Blood (2015) 126 (23): 3047.

https://doi.org/10.1182/blood.V126.23.3047.3047

Published: 2015

Journal Articles

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Torben Plesner, MD, Hendrik-Tobias Arkenau, Peter Gimsing, Jakub Krejcik, Charlotte Lemech, Monique C. Minnema, Ulrik Lassen, Jacob P. Laubach, MD, Antonio Palumbo, Steen Lisby, Linda Basse, Jianping Wang, A Kate Sasser, Mary E Guckert, Howard Yeh, Tahamtan Ahmadi, Henk M. Lokhorst, Paul G. Richardson

Blood (2015) 126 (23): 507.

https://doi.org/10.1182/blood.V126.23.507.507

Published: 2015

Journal Articles

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

Torben Plesner, MD, Hendrik-Tobias Arkenau, MD, Henk M. Lokhorst, MDPhD, Peter Gimsing, MD PhD, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MDPhD, Ulrik Lassen, MDPhD, Jacob P. Laubach, MD, Tahamtan Ahmadi, MD PhD, Howard Yeh, MD, Mary E Guckert, MSN, RN, Huaibao Feng, Nikolai Constantin Brun, MDPhD, Steen Lisby, Linda Basse, MDDMSc, Antonio Palumbo, MD, Paul G. Richardson

Blood (2014) 124 (21): 84.

https://doi.org/10.1182/blood.V124.21.84.84

Published: 2014

Journal Articles

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Marita Westhrin, MSc, Siv Helen Moen, PhD, Toril Holien, PhD, Oddrun Elise Olsen, MSc, Anne Kærsgaard Mylin, MDhD, Peter Gimsing, MD PhD, Ingemar Turesson, MD PhD, Anders Waage, MD PhD, Therese Standal, PhD

Blood (2014) 124 (21): 2065.

https://doi.org/10.1182/blood.V124.21.2065.2065

Published: 2014

Journal Articles

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Torben Plesner, MD, Tobias Arkenau, MD, Henk Lokhorst, Peter Gimsing, MD, DMSci, Jakub Krejcik, MD, Charlotte Lemech, MD, Monique C. Minnema, MD PhD, Ulrik Lassen, MD PhD, Andrew Cakana, FRCPath, MD, Nikolai Constantin Brun, MD PhD, Linda Basse, MD DMSc, Antonio Palumbo, MD, Paul G. Richardson, MD

Blood (2013) 122 (21): 1986.

https://doi.org/10.1182/blood.V122.21.1986.1986

Published: 2013

Journal Articles

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Blood (2013) 121 (23): 4647–4654.

https://doi.org/10.1182/blood-2012-11-464503

Published: 2013

Journal Articles

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Torben Plesner, MD, Henk Lokhorst, MD, PhD, Peter Gimsing, MD, PhD, Hareth Nahi, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2012) 120 (21): 73.

https://doi.org/10.1182/blood.V120.21.73.73

Published: 2012

Journal Articles

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

Meral Beksac, MD, Anders Waage, MD, PhD, Sara Bringhen, MD, Sigurdur Y Kristinsson, MD PhD, Gulsan Sucak, MD, Peter Gimsing, MD, PhD, Lupparelli Giulia, PhD, Tulin Firatli Tuglular, MD, Gunnar Juliusson, MD PhD, Antonio Palumbo, MD

Blood (2011) 118 (21): 3970.

https://doi.org/10.1182/blood.V118.21.3970.3970

Published: 2011

Journal Articles

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

Peter Gimsing, MD, DMSci, Assoc. Prof., Torben Plesner, MD, Hareth Nahi, Henk Lokhorst, MD, PhD, Marie-Louise Valentin, MD, Steen Lisby, MD, DMSc, Paul G. Richardson, MD

Blood (2011) 118 (21): 1873.

https://doi.org/10.1182/blood.V118.21.1873.1873

Published: 2011

Journal Articles

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Peter Gimsing, MD, DMSci, Assoc. Prof., Oyvind Hjertner, Niels Abildgaard, Niels Frost Andersen, Tobias Gedde Dahl, Henrik Gregersen, MD, Ulf-Henrik Mellqvist, MD, PhD, Olle Linder, Roald Lindas, Niels-Aage Tøfner Clausen, Stig Lenhoff

Blood (2011) 118 (21): 3073.

https://doi.org/10.1182/blood.V118.21.3073.3073

Published: 2011

Journal Articles

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Blood (2011) 118 (17): 4519–4529.

https://doi.org/10.1182/blood-2011-06-358812

Published: 2011

Journal Articles

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Blood (2011) 118 (5): 1239–1247.

https://doi.org/10.1182/blood-2011-03-341669

Published: 2011

Journal Articles

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Blood (2010) 116 (9): 1405–1412.

https://doi.org/10.1182/blood-2009-08-237974

Published: 2010

Journal Articles

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Blood (2009) 114 (22): 530.

https://doi.org/10.1182/blood.V114.22.530.530

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study

Validation of a New Clinical Prediction Model for Outcome in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem-Cell Transplantation; A Population-Based Study from the Danish National Multiple Myeloma Registry

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Cereblon Is Downregulated By Promoter Nucleosome Occupancy in Acquired IMiD Resistance: The Potential of IMiD Resensitization By Epigenetic Therapy

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and/or Refractory Multiple Myeloma (RRMM): The Phase 3 Tourmaline-MM1 Study (NCT01564537)

The Rev II Trial: Lenalidomide and Dexamethasone As Second Line Treatment in Myeloma Followed By Extended Lenalidomid Vs Len/Dex

Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1/2 Study (GEN503)

Safety and Efficacy of Daratumumab with Lenalidomide and Dexamethasone in Relapsed or Relapsed, Refractory Multiple Myeloma

GDF15 Promotes Osteoclast Differentiation and High Serum GDF15 Levels Are Associated with Multiple Myeloma Bone Disease

Preliminary Safety and Efficacy Data Of Daratumumab In Combination With Lenalidomide and Dexamethasone In Relapsed Or Refractory Multiple Myeloma

Bortezomib consolidation after autologous stem cell transplantation in multiple myeloma: a Nordic Myeloma Study Group randomized phase 3 trial

Daratumumab, a CD38 Monoclonal Antibody in Patients with Multiple Myeloma - Data From a Dose-Escalation Phase I/II Study

Does Heparin Have An Anti-Myeloma Effect? An Analysis On Individual Data From Three Randomized Studies of GIMEMA, Nordic and Turkish Myeloma Study Groups,

A Phase I/II, Dose-Escalation Study of Daratumumab, A CD38 Mab in Patients with Multiple Myeloma – Preliminary Safety Data

A Phase II Study of Bortezomib-Dexametason Followed by High-Dose Melphalan Combined with Bortezomib in Patients Relapsing After High-Dose Melphalan with Autologous Stem Cell Support

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials

Melphalan and prednisone plus thalidomide or placebo in elderly patients with multiple myeloma

Improved Response Rate with Bortezomib Consolidation After High Dose Melphalan: First Results of a Nordic Myeloma Study Group Randomized Phase III Trial.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only